Evening of 16th November 2017
Inauguration evening of Par'Immune
Par’Immune is a biopharmaceutical company co-founded by Professor Monique Capron and Dr. Abderrahim Lachgar, dedicated to the development of an innovative drug candidate of parasitic origin, the P28GST. This candidate targeting autoimmune and inflammatory diseases is currently being evaluated in a Phase 2a clinical trial in patients with Crohn’s disease. In early 2018, the company will initiate its development plan to conduct two Phase 2b clinical trials in various inflammatory diseases.